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ABSTRACT
Chemoradiation therapy is widely used to treat both inoperable and operable patients, and is less invasive than
surgery. Although the number of long-term survivors who have received chemoradiation therapy is increasing,
the long-term toxicity pattern and cumulative incidence of toxicity regarding this modality are poorly under-
stood. Classically, chemoradiation therapy for esophageal cancer consists of an anterior–posterior ﬁeld and a
subsequent oblique boost ﬁeld. We retrospectively analyzed patients who were treated with deﬁnitive chemora-
diation therapy for esophageal cancer using this classical method from 1999 to 2008. For the assessment of tox-
icity, the National Cancer Institute Common Toxicity Criteria Version 3.0 was adopted. A total of 101 patients
were analyzed. The median follow-up time was 16 months for all patients and 62 months for the surviving
patients. Eleven patients experienced late toxicities of ≥Grade 3. Two patients died of late toxicities. The 3- and
5-year cumulative incidences for the ﬁrst late cardiopulmonary toxicities of ≥Grade 3 were 17.4% and 20.8%,
respectively. Cardiopulmonary effusions were observed within the ﬁrst 3 years of completion of the initial treat-
ment in seven out of eight patients. Sudden death and cardiac ischemia were observed over a 10-year period.
Older age was found to be a risk factor for late toxicity after deﬁnitive chemoradiation therapy for esophageal
cancer. Substantial toxicities were observed in patients who had received chemoradiation therapy for esophageal
cancer using the classical method. To minimize the incidence of late toxicity, more sophisticated radiation tech-
niques may be useful.
KEYWORDS: esophageal cancer, chemoradiation therapy, long-term complications, cardiopulmonary toxicity,
second malignancy, cumulative incidence
INTRODUCTION
Surgery is the standard treatment for operable esophageal cancer [1,
2]. However, the type of surgery required for this cancer is highly
invasive, and the quality of life of patients who undergo such sur-
gery is poor. Because patients with esophageal cancer sometimes
have other severe comorbidities, less invasive therapy has been
explored in patients who are not candidates for surgery. Historically,
radiation therapy alone has been the standard therapy for unresect-
able or medically inoperable patients, but the outcomes of patients
treated with this modality have not been satisfactory.
After the publication of a report concerning the intergroup ran-
domized controlled trial (RTOG-8501), which demonstrated the
superiority of concurrent chemoradiation therapy (CRT) over radi-
ation therapy alone, combined-modality treatment became the
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standard nonsurgical treatment for esophageal cancer [3–5]. In
terms of quality of life and acute toxicities, CRT is considered to
have an advantage over surgery. In a preliminary report, the out-
come of CRT was found to be similar to that of surgery [6–9]. For
these reasons, CRT has become a treatment option not only for
unresectable or medically inoperable patients but also for operable
patients. The number of esophageal cancer patients treated with
CRT has been increasing in Japan.
Unfortunately, as the number of long-term survivors increases
after CRT, late complications such as heart failure, pleural effusion,
pericardial effusion, and ischemic heart disease have become pro-
blems [10–12]. Some patients have died from late toxicities without
cancer recurrence. Several factors have been reported as risk factors
for radiation-induced late toxicities. However, especially over a
5-year period, the long-term complication pattern and cumulative
incidence of toxicities have not been well described.
Radiation therapy for esophageal cancer classically consists of an
anterior–posterior ﬁeld and a subsequent oblique opposed ﬁeld to
shield the spinal cord. In the present study, we examined the inci-
dence and pattern of long-term complications and the cumulative
incidence of toxicities that occurred after deﬁnitive CRT involving
the use of this classical ﬁeld technique for esophageal cancer.
MATERIALS AND METHODS
Study design
This was a retrospective study regarding the late toxicities of CRT
for esophageal cancer. The study was approved by the Institutional
Ethical Review Board of the Kyoto University Hospital.
Patient characteristics
Between 1999 and 2008, 135 patients with thoracic esophageal
cancer underwent deﬁnitive CRT at our institute. All patients had
histologically conﬁrmed esophageal cancer. Clinical stage was deter-
mined using computed tomography, X-ray ﬂuoroscopy, and endos-
copy. Endoscopic ultrasound of the esophagus, bronchoscopy, and
whole-body ﬂuorodeoxyglucose-positron emission tomography were
used as appropriate. Tumor stage was classiﬁed according to the
TNM classiﬁcation of the Union for International Cancer Control,
6th edition.
A total of 34 patients were excluded from this analysis; 33
patients were not treated with an anterior–posterior opposed ﬁeld
and subsequent oblique opposed ﬁeld. The characteristics of the
remaining 102 patients are listed in Table 1. The median age of the
patients was 65 (range, 41–82) years. One patient had adenocarcin-
oma, one patient had squamous cell carcinoma and adenocarcinoma
simultaneously, and the remaining patients had squamous cell
carcinoma.
Radiation therapy technique
Radiation therapy was delivered using megavoltage equipment
(6–15 MV). Initially, radiation therapy was performed using the
anterior–posterior ﬁeld technique, and total doses of 40–41.4 Gy
were delivered in 1.8–2-Gy fractions. The initial clinical treatment
volumes (CTVs) were basically designed as follows: the upper
mediastinum, which extends from the cervical lymph nodes to
Table 1. Patient characteristics
Characteristics n = 102





Squamous cell carcinoma 100
Adenocarcinoma 1
Squamous cell carcinoma+ adenocarcinoma 1





UICC N stage (6th)
N0 13
N1 89



















UICC=Union for International Cancer Control; Ut= upper third of thoracic
esophagus, esophagus; Mt=middle third of thoracic esophagus; Lt = lower third
of thoracic esophagus; Ae = abidominal esophagus.
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~3 cm below the tracheal bifurcation for upper-thoracic tumors; the
whole mediastinum for middle-thoracic tumors; and the mediasti-
num and celiac and perigastric lymph nodes for lower thoracic
tumors. The CTV for some early-stage patients was designed to
include the primary lesion together with a 2- to 3-cm craniocaudal
margin. The planning target volume (PTV) added a 0.5-cm margin
to the CTV in the lateral and anterior/posterior direction and a
1-cm margin in the craniocaudal direction. The leaf margin was
equivalent to the PTV plus 0.5 cm.
A radiation boost dose was delivered using an oblique opposed
ﬁeld to spare the spinal cord. The CTV for the boost dose consisted
of the primary lesion plus 2–3 cm of the craniocaudal margin, and
the metastatic lymph node plus a 0.5- to 1-cm margin. Areas of
prophylactic irradiation were omitted from the CTV for the boost
dose. The arrangement between the CTV and the PTV and leaf
margins was the same as that used for the initial ﬁeld.
Details of treatment
Details of the treatment are summarized in Table 2A and 2B. A
total of 87 patients received radiation therapy at a cumulative dose
of ≤60 Gy. The median radiation dose was 60 (range, 50–66.6) Gy.
The median initial ﬁeld length and boost ﬁeld length were 24.0
(range, 13.5–30) cm and 15.4 (range, 5.5–28) cm, respectively.
Four patients received an intraluminal brachytherapy median boost
dose of 3.5 (range, 3–4) Gy after external beam irradiation (median
60 [range, 60–66] Gy) therapy. Total treatment time was 6–8 weeks.
The chemotherapy regimens used mainly consisted of platinum
agents plus 5-ﬂuorouracil (5-FU) chemotherapy. A total of
83 patients received chemotherapy according to the KROSG-0101/
JROSG-021 chemotherapy protocol [13]. Six patients received sal-
vage surgery; among them, one patient died from postoperative
complications. Two patients underwent salvage endoscopic therapy.
Follow-up
After the initial therapy, CT and endoscopic observation was performed
every 1–3 months in the ﬁrst year, 3–6 months in the second to ﬁfth
year, and annually after 5 years. When symptoms appeared, other sur-
veys were mandatory for the attending physicians. Locoregional recur-
rence, distant metastasis, and cardiopulmonary toxicities were evaluated
by means of barium swallow, upper gastrointestinal endoscopy, ultra-
sound scan, chest X-ray, or a thoraco-abdominal computed tomography
scan. For the assessment of toxicity, the National Cancer Institute
Common Toxicity Criteria Version 3.0 was adopted. On the basis of
onset time, CRT toxicities were classiﬁed as acute toxicities or late toxi-
cities at 6 months after the start of the treatment.
Statistical analysis
Analysis of survival and the incidence of late complications was per-
formed using the Kaplan–Meier method. Univariate analysis of late
toxicity was carried out using the Cox hazard model. Two-group ana-
lysis of the cumulative incidence of differences in late toxicity was
conducted using the Grey test. The time to event was calculated from
the start of radiation therapy. Univariate analysis was performed in
relation to age, tumor location, initial ﬁeld length, boost ﬁeld length,
chemotherapy regimen, total dose, and sex. A P value of <0.05 was
considered statistically signiﬁcant. Statistical analyses were performed
using EZR software (Saitama Medical Center, Jichi Medical
University, Saitama, Japan), which is a graphical user interface for R
(The R Foundation for Statistical Computing, Vienna, Austria) [14].
RESULTS
Survival
Overall survival as estimated using the Kaplan–Meier method is
shown Fig. 1. The median follow-up time was 16 months. The com-
plete response rate in the initial evaluation was 30%. The median
follow-up period for surviving patients was 62 (range, 2–140)
months, and the median survival time for all patients was 16
months. The 3- and 5-year overall survival rates for all patients were
32.9% and 26.8%, respectively.
Acute toxicity (excluding hematological toxicity)
Non-hematological acute toxicities of ≥Grade 3 are summarized in
Table 3A. They were as follows: six Grade 4 and two Grade 5
esophageal ﬁstulas; one Grade 4 and one Grade 5 hepatic failure;
one Grade 5 radiation pneumonitis; and one Grade 5 sudden death
Table 2A. Details of the radiation therapy technique
Parameters









Table 2B. Combined chemotherapy regimens
Chemotherapy regimen n= 102
CDDP+ 5-FU 63






CDDP = cisplatin; 5-FU= 5-ﬂuorouracil; CBDCA = carboplatin; CDGP=
nedaplatin; S-1= TS-1; tegafur, gimeracil, oteracil potassium.
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within 6 months after the start of CRT. Two patients died of aorta–
esophageal ﬁstulas at 55 and 82 days after the start of CRT. All
patients who experienced esophageal ﬁstulas had clinical T4–T3
stage disease at diagnosis. One patient died from acute hepatic fail-
ure at 3 months after the start of radiation therapy and before the
assessment of therapeutic response, which was highly suggestive of
5-FU–related acute toxicity. One patient died from radiation pneu-
monitis at 4 months after treatment without cancer recurrence. One
patient with cancer died suddenly at 6 months after treatment.
Late toxicity
The late complications of ≥Grade 3 that occurred after CRT are
summarized in Tables 3B and 4. Seventeen late toxicities of ≥Grade
3 were observed in 11 patients. Two patients died of late toxicities.
One patient died suddenly at 150 months after treatment without
cancer recurrence. One patient died from acute myeloid leukemia at
77 months after treatment without esophageal cancer recurrence.
Regarding cardiopulmonary effusions, there were four Grade 3
pericardial effusions and eight Grade 3 pleural effusions. All four
patients who had Grade 3 pericardial effusions also had Grade 3
pleural effusions; both pericardial and pleural effusion were
observed simultaneously at 13, 16, 23 and 40 months after treat-
ment. In our study, no patients died from chronic heart failure
during the follow-up period. All cases of cardiopulmonary effusions
were manageable with diuretics, chest tube drainage, or pleurodesis.
No cases of cardiopulmonary effusion were observed in patients
whose primary tumor was exclusively located in the upper third of
the thoracic esophagus. As for other cardiopulmonary toxicities, one
acute myocardial infarction, one cardiac arrest, and one radiation
pneumonitis that required oxygen support were observed.
The cumulative incidence and timing of late toxicity
The estimated cumulative incidence of the ﬁrst late cardiopulmonary
toxicity episodes of ≥Grade 3 as calculated using the Kaplan–Meier
method is shown in Fig. 2. The overall 3- and 5-year cumulative inci-
dence rates were 17.4% and 20.8%, respectively. The ﬁrst late toxici-
ties occurred within the ﬁrst 3 years of the completion of the initial
treatment in eight out of 11 patients. In particular, the ﬁrst pericardial
and pleural effusions were observed within the ﬁrst 3 years of comple-
tion of the initial treatment in seven out of eight patients.
The factor of late toxicity
Univariate analysis was performed in relation to age, location, initial
ﬁeld length, boost ﬁeld length, sex, chemotherapy regimen, and total
dose. Results regarding the analysis of ﬁrst late toxicities are shown
in Table 5. The cut-off point for continuous variables was the
median value. The patients whose primary tumor was located exclu-
sively in the thoracic esophagus did not have pleural effusion or
pericardial effusion; however, the primary tumor location was not a
risk factor regarding late cardiopulmonary toxicity in this study. In
univariate analysis, age was found to be the only risk factor for late
cardiopulmonary toxicity. When the patients were divided into two
groups based on age (≤65 years and >65 years), the older group
was found to have experienced signiﬁcantly more late toxicity (Grey
test, P = 0.029; Fig. 3). The 5-year incidence of late toxicity was
6.8% in the younger group and 38.4% in the older group.
DISCUSSION
Surgery is the standard treatment for operable esophageal cancer.
However, the type of surgery required for this cancer is highly inva-
sive. Because patients with esophageal cancer sometimes have other
severe comorbidities, less invasive therapy has been explored not
only in patients who are not candidates for surgery but also in oper-
able patients. After a number of studies had reported good out-
comes regarding CRT for esophageal cancer [6–9], this modality
Fig. 1. Overall survival of all patients.
Table 3A. Acute toxicities of >Grade 3
Grade 3 4 5
Esophageal ﬁstula 0 6 2
Hepatic failure 0 1 1
Radiation pneumonitis Not assessed 0 1
Sudden death 0 0 1
Table 3B. Late toxicities of >Grade 3
Grade 3 4 5
Pleural effusion 8 0 0
Pericardial effusion 4 0 0
Pneumonitis 1 0 1
Cardiac ischemia 1 1 0
Sudden death 0 0 1
Secondary malignancy 0 0 1
Long-term complications of deﬁnitive chemoradiotherapy for esophageal cancer • 109















1 5 70 Mt–Lt Sudden death 150 Died without relapse Sudden death CDDP+ 5-FU
continuous infusion
50 22 9.0
2 5 67 Ut–Mt Secondary
malignancy
77 Died with secondary
malignancy
AML CDDP+ 5-FU 60 24 18.0
3 Pleural effusion 35
3 4 73 Ut–Mt Cardiac ischemia 57 Died without relapse ARDS CDDP+ 5-FU
continuous infusion
60 24 12.1




4 3 74 Mt Cardiac ischemia 151 Died with lung cancer
(out of ﬁeld)
Lung cancer CDDP+ 5-FU
continuous infusion
55 26 19.8
5 3 58 Lt Pleural effusion 22 Died with relapse Esophageal
cancer




6 3 74 Ut–Mt Pleural effusion 20 Died without relapse Infectious
pneumonitis
CDDP+ 5-FU 64 21.5 10.0
7 3 80 Ut–Mt Pleural effusion 19 Died with relapse Esophageal
cancer
CDDP+ 5-FU 60 24 11.3








9 3 68 Mt–Lt Pleural effusion 14 Died with relapse Esophageal
cancer
CDDP+ 5-FU 60 28.2 20.2







has gradually become the treatment of choice for esophageal cancer,
not only in inoperable patients but also in operable patients. In
terms of quality of life and acute toxicities, CRT is considered to
have an advantage over surgery. However, in long-term follow-up,
late toxicities associated with CRT for esophageal cancer have
become a problem [10–12]. The most common late CRT toxicities
are pericardial effusion and pleural effusion. Although almost all of
these complications can be managed with diuretics, needle drainage,
or pleurodesis, they not only affect patient quality of life but can
also occasionally be fatal [8, 15]. In previous studies, although treat-
ment regimens, ﬁeld set-up, patient background, and evaluation of
late toxicity were individualized, 5–16% of patients experienced
some type of severe cardiopulmonary late toxicity after classical radi-










































































































































































Fig. 2. Cumulative incidence of ﬁrst cardiopulmonary late
toxicities.





Age (years) >65/≤65 0.046 4.93 1.03–23.64
Initial ﬁeld length (cm) >24.4/≤24.4 0.49 1.57 0.43–5.70





Radiation dose (Gy) ≥60/<60 0.96 0.95 0.11–8.35
Location, Ut/lower than Ut 0.56 0.52 0.058–4.68
Ut= upper third of thoracic esophagus.
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ﬁeld and a subsequent booster dose delivered to an oblique
opposed ﬁeld [10–12]. In the present study, 12.1% of patients
experienced late toxicities, and their cumulative rate at 5 years was
~20%. Morota et al. and Kato et al. reported that the cumulative
rate of late toxicities was ~30% [8, 12]. With 10 years’ additional
follow-up, we found that the cumulative incidence of severe cardio-
pulmonary effusions did not increase year on year, but rather had
plateaued at ~3 years. The most severe cardiopulmonary toxicities
were also seen within 3 years in previous studies [10–12].
We performed univariate analysis concerning the risk factors for
late cardiopulmonary toxicities; age was found to be the only signiﬁ-
cant risk factor. Previous studies have also reported that older patients
are at high risk of late complications [12, 16]. Generally, elderly
patients have a low performance status and multiple comorbidities. In
a previous report, patients whose performance status was 2 had a
greater risk regarding cardiopulmonary effusions than patients with a
performance status of 0–1 [16]. However, in general, the perform-
ance status of patients who have received platinum-containing CRT
is assumed to be 0–1; this was also the assumption made in our
study. Mild cardiopulmonary comorbidities may not be a risk factor
for cardiopulmonary complications, as previously reported [16, 17].
The incidences of ischemic heart disease and sudden death that
have been reported in previous studies were 1.4–3.7% [10–12, 15],
and they were 3% in our study. Although sudden death may be the
result of radiation-induced heart arrhythmias, if it is associated with
Grade 5 ischemic heart disease, cardiac ischemia can be seen not only
at <3 years after CRT but also at >10 years after CRT, unlike pericar-
dial effusion and pleural effusion. This ﬁnding is in accordance with
the ﬁndings of previous studies involving late complications associated
with radiation therapy for Hodgkin’s lymphoma and breast cancer
[18]. In an analysis of postoperative radiation therapy for breast cancer,
a history of prior ischemic heart disease and greater age increased the
risk of post–radiation therapy ischemic heart disease [19]. We should
be aware that patients who have such a background tend to be treated
using CRT, but they are at high risk of post-radiation ischemic heart
disease. In previous studies, chronic heart failure was reported to have
occurred at rates of 1.4–3.7% [10–12]. Sometimes patients died from
chronic heart failure. However, in our study, no patients died from this
condition during the follow-up period.
Although tumor location was not a signiﬁcant risk factor for late
cardiopulmonary toxicities in univariate analysis in our study, car-
diac toxicities and pleural effusions only occurred after irradiation of
the middle to lower third of thoracic esophageal cancer. The middle
to lower thoracic area may be the organ at risk (OAR) of cardiopul-
monary effusions, because the radiation ﬁeld is terminated at the
subcarina level in upper third thoracic esophageal cancer.
Secondary malignancies also remain a concern after CRT. In our
analysis, one patient died from acute myeloid leukemia at 77
months after treatment without cancer recurrence. Chang et al. also
reported two acute myeloid leukemia cases at 55 and 20 months
after deﬁnitive CRT for esophageal cancer [20]. The necessity of
longer follow-up times should be emphasized after CRT. In our
study one patient died from lung cancer, but the lung cancer pri-
mary site was located outside of the irradiation ﬁeld.
To reduce the risk of these late toxicities, we should make efforts
to improve the quality of radiation therapy because most late toxici-
ties are assumed to be caused by radiation therapy. Using a more pre-
cise therapy technique such as radiation therapy involving multiple
ﬁeld irradiation, intensity-modulated radiation therapy [21], or par-
ticle beam therapy [22] may also be beneﬁcial. With these techniques,
we can deliver an optimal radiation dose to the clinical target without
increasing the dose delivered to the OAR. In a retrospective study,
Lin et al. reported that overall survival, non-cancer-related death, and
the cumulative incidence of cardiac death had been signiﬁcantly
improved after intensity-modulated radiation therapy relative to 3D
radiation therapy [21]. This study suggested that the use of the latest
precision radiation therapy techniques can increase overall survival,
not only by improving local tumor control but also by reducing
radiation-related toxicities by avoiding OARs. Another method that
can be used to reduce the dose to OARs is the elimination of elective
nodal irradiation, although this approach is still controversial [23].
Although many Japanese radiation oncologists continue to pre-
scribe a total dose of 60 Gy for esophageal cancer [15], a randomized
study has demonstrated the superiority of radiation therapy at total
doses of 50.4 Gy over 64.8 Gy [24]. To take into account long-term
complications, Japanese radiation oncologists should consider a
reduction in the prescribed dose to reduce OAR dose exposure.
A Japanese Phase II study that will evaluate CRT at a total dose of
50.4 Gy, including salvage treatment (JCOG0909), has been planned
and has ended accrual. The ﬁndings of this study could result in the
prescribed dose being changed for esophageal cancer in Japan.
We evaluated the long-term toxicity pattern and cumulative
incidence associated with CRT for esophageal cancer using an
anterior–posterior ﬁeld and a subsequent oblique boost ﬁeld. CRT
is an effective and less invasive therapy than surgery, but has sub-
stantial long-term toxicity. We should assess the results of CRT
with long-term toxicity in mind. Further investigation aimed at ﬁnd-
ing ways to minimize the incidence of late toxicity, such as using
Fig. 3. Cumulative incidence of cardiopulmonary late
toxicities divided by age. Grey test, P= 0.029.
112 • H. Ito et al.
more sophisticated radiation therapy techniques and/or reducing
the prescribed doses, is warranted.
The present study had a number of limitations. It was retro-
spective and involved only one institute; it also entailed the use of a
non-uniform protocol, and lacked detailed patient background data.
However, because the long-term complication patterns and the
cumulative incidence of deﬁnitive CRT for esophageal cancer have
not been well described, we believe that our study has value.
CONCLUSION
Approximately 20% of patients who received deﬁnitive CRT for
esophageal cancer using the classical method had substantial long-
term toxicity. With 10 years’ additional follow-up, we found that the
cumulative incidence of severe cardiopulmonary effusions did not
increase year on year, but rather had plateaued at ~3 years. Older age
was a risk factor for long-term toxicities. To minimize the incidence
of late toxicity, more sophisticated radiation techniques may be useful.
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